Snapshot from Aug 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Procept BioRobotics securities class action
Regulatory class action

Procept BioRobotics securities class action

Analysis based on 7 articles · First reported Aug 03, 2026 · Last updated Aug 07, 2026

Sentiment
-60
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit and the underlying disclosures of inventory issues and declining sales have negatively impacted investor confidence in PROCEPT BioRobotics, leading to substantial stock price declines. The company faces potential legal liabilities and reputational damage, which could further pressure its market valuation.

Medical Devices
Event Summary

Pomerantz LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (Nasdaq: PRCT) alleging securities fraud and unlawful business practices. The complaint centers on the company's disclosures regarding handpiece sales and inventory. Specifically, Procept reported lower-than-expected handpiece sales in Q2 2025, reduced its annual guidance in Q3 2025, and in February 2026 revealed cumulative excess field inventory of over 10,000 units and a nearly 30% sequential decline in quarterly unit sales. These disclosures caused significant stock price declines of 16%, 10%, and 18% respectively. Investors who purchased Procept securities during the class period have until September 22, 2026, to seek lead plaintiff appointment.

Key Actions
90 Pomerantz LLP filed class action PROCEPT BioRobotics
90 PROCEPT BioRobotics missed sales guidance
Entities Involved
stock
PROCEPT BioRobotics
The defendant in the class action, facing allegations of securities fraud and significant stock price declines due to inventory and sales disclosures.
Importance 100.0 Sentiment -80.0
priv
Pomerantz LLP
The law firm that filed the class action, representing investors and potentially benefiting from legal fees if successful.
Importance 70.0 Sentiment 20.0
per
Kevin Waters
CFO who provided guidance and admitted to inventory issues, implicated in the alleged securities fraud.
Importance 40.0 Sentiment -50.0
per
Reza Zadno
Former CEO who eliminated the Chief Commercial Officer role, part of the alleged misleading conduct.
Importance 30.0 Sentiment -40.0
per
Larry L. Wood
CEO who admitted to poor inventory management, contributing to the alleged fraud.
Importance 30.0 Sentiment -40.0
exch
Nasdaq
The exchange where Procept is listed, not directly impacted but relevant as the trading venue.
Importance 10.0 Sentiment 0.0
Relationships
Pomerantz LLP related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.